GRANTS

274 RESULTS

To submit a grant posting, please fill out our web form or download the form so that you can email us at grants@alzforum.org. List the sponsor name, amount, due date, and contact information. This is a free service.

Please Note: We remove grant postings after 6 months. If you would like your listing to be posted longer or taken down sooner, please contact us at grants@alzforum.org.

Alzheimer's Disease Research Centers (P30 - Clinical Trials Not Allowed)

Sponsor: National Institute on Aging

Award: NIH intends to commit $16 million in FY 2019 to fund an estimate of five to seven awards.

Due Date: June 4, 2018, by 5 p.m. local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. No late applications will be accepted for this Funding Opportunity Announcement. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Pragmatic Trials for Dementia Care in Long-term Services and Support (LTSS) Settings (R61/R33 - Clinical Trial Required)

Sponsor: National Institute on Aging

Award: The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Due Date: March 27, 2018; February 20, 2019; and February 20, 2020 , by 5 p.m. local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

2019 McKnight Memory and Cognitive Disorders Award

Sponsor: McKnight Endowment Fund for Neuroscience

Award: Up to four awards are made annually, each providing $100,000 per year for three years.

Due Date: Letters of intent are due on March 26, 2018 (midnight in the last time zone on earth). Full proposals will be due September 10, 2018. Funding begins on February 1, 2019.

Emotional Function in Normal Aging and/or MCI and AD/ADRD (R01 - Clinical Trial Optional) (PAR-18-581)

Sponsor: National Institute on Aging

Award: NIA intends to commit $2.5 million in FY 2018 to fund five to eight awards in response to this FOA and its companion R21 FOA PAR-18-582. The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Due Date: March 29, 2018; June 8, 2018; February 8, 2019; June 7, 2019; February 7, 2020; and June 8, 2020, by 5 p.m. local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

Emotional Function in Normal Aging and/or MCI and AD/ADRD (R21 - Clinical Trial Not Allowed) (PAR-18-582)

Sponsor: National Institute on Aging

Award: NIA intends to commit $2.5 million in FY 2018 to fund five to eight awards in response to this FOA and its companion R21 FOA PAR-18-581. The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Due Date: March 29, 2018; June 20, 2018; February 20, 2019; June 20, 2019; February 20, 2020; and June 22, 2020, by 5 p.m. local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

Alzheimer's Clinical Trials Consortium (ACTC) Clinical Trials (R01 Clinical Trial Required)

Sponsor: National Institute on Aging

Award: The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. NIH intends to fund an estimate of five to seven awards, corresponding to a total of $10 million, for fiscal year 2018. Future year amounts will depend on annual appropriations.

Due Date: The first application due date is March 29, 2018, by 5 p.m. local time of the applicant organization. Subsequently, standard dates apply, by 5 p.m. local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

Biobehavioral and Technological Interventions to Attenuate Cognitive Decline in Individuals with Cognitive Impairment or Dementia (R21 Clinical Trial Optional)

Sponsor: National Institutes of Health

Award: The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Due Date: Standard dates apply, by 5 p.m. local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Biobehavioral and Technological Interventions to Attenuate Cognitive Decline in Individuals with Cognitive Impairment or Dementia (R01 Clinical Trial Optional)

Sponsor: National Institutes of Health

Award: The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Due Date: Standard dates apply, by 5 p.m. local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Understanding the Effects of ApoE2 on the Interaction between Aging and Alzheimers Disease (R01 - Clinical Trial Not Allowed)

Sponsor: National Institute on Aging

Award: NIA intends to commit up to $3 million (total costs) in FY 2018 to support three to five awards. The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Due Date: March 28, 2018, by 5 p.m. local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. No late applications will be accepted for this Funding Opportunity Announcement. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Consequences of amyloid protein polymorphisms in Alzheimer's disease (R01 - Clinical Trial Not Allowed)

Sponsor: National Institute on Aging

Award: NIA intends to commit $6 million in FY 2018 to fund eight to 10 awards. The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Due Date: March 28, 2018, by 5 p.m. local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.

BRAIN Initiative: Next-Generation Invasive Devices for Recording and Modulation in the Human Central Nervous System (UG3/UH3 - Clinical Trial Required)

Sponsor: National Institutes of Health

Award: The NIH anticipates providing $10 million per year to fund an estimated five to seven awards.

Due Date: February 23, 2018, June 21, 2018, October 22, 2018, February 21, 2019, June 21, 2019, October 21, 2019, February 21, 2020, June 22, 2020, October 21, 2020 , by 5 p.m. local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

Current Filters

No filters selected

Filter By